At the intersection of health and the climate is an urgent crisis. This crisis affects health in ways that are wide-ranging, ...

In this report, we investigate the theory and practice of value-based pricing in the pharmaceuticals industry, and provide recommendations for how implementation of value-based pricing can be enhanced ...

Antimicrobial resistance (AMR) is an urgent global health crisis. AMR infections cause an estimated 1.3 million deaths globally every year, and this number is only projected to rise.

A biennial prize fund to promote thought leadership around the big questions affecting health economics. OHE’s educational mission is to support, sustain, and enhance the discipline of health ...

For the growing number of multi-indication medicines, access may be delayed or even denied due to challenges in linking payment with a medicine’s value across those indications. We assembled a broad ...

This report examines the importance and history of HTA evaluations for additional uses for cancer drugs after their initial approval. Included are the ten cancer drugs approved by the EMA during ...

A biennial prize fund to promote thought leadership around the big questions affecting health economics. OHE’s educational mission is to support, sustain, and enhance the discipline of health ...

Adult vaccines can return up to 19 times their initial investment to society, when their significant benefits beyond the healthcare system are monetised.

This research reviews how vaccines other than for travel or influenza are evaluated, procured and delivered in the UK. It includes observations as to whether and how the economic assessment process ...

Earlier today, the UK government unveiled the long-awaited NHS Ten Year Plan. Commenting on the Plan, Professor Graham Cookson, Chief Executive of the Office of Health Economics, said: “The hotly ...

Fertility treatments, collectively termed Assisted Reproductive Techniques (ART), are now widely available for routine clinical use. However, there is a lack of cost-effectiveness evidence for ...

US drug pricing policies will have global impacts on innovation and access The knowledge generated through biomedical innovation is a public good. One person’s use does not reduce its availability to ...